Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Inclusion Criteria: * Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; * Men and Women ≥ 18years of age; * Internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period; * COVID-19 infection confirmed with a laboratory antigen or SARS-CoV-2 RT-PCR nasal swab; * Specimen collected within the past 48 hours; * Mild COVID /FLU symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; * Must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge); * Hormonal methods and the IUD must be in use at least 30 days prior to first Study drug administration * Abstinence and barrier methods must be in use at least 14 days prior to Study drug administration * Vasectomy must be completed 3 months prior to first Study drug administration; or in the alternative that a 0 sperm count will suffice. Exclusion Criteria: * Current tracheostomy or laryngectomy; * Concomitant respiratory therapy such as oxygen or ventilatory support. Positive airway pressure for obstructive sleep apnea is permitted if treatment was established with good compliance at least 3 months before enrolment; * Need for hospitalization for any reason; * Inability to safely self-administer nasal irrigation * Any clinical contraindications, as judged by the Qualified Medical Practitioner; * Clinical signs indicative of moderate, severe or critical COVID severity symptoms (as defined by FDA COVID-19 Guidance Document) * Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study; * Lactating, pregnant or planning to become pregnant during the study period; * Diagnosed with prior COVID-19 infection (\>48 hours from the time the test is reported prior to the time of screening).